Enzyme replacement therapy in feline mucopolysaccharidosis I

Molecular Genetics and Metabolism

Volumn 72, Issue 3, 2001, Pages 199-208

  Kakkis, E D ^a   Schuchman, E ^b   He, X ^b   Wan, Q ^b   Kania, S ^b   Wiemelt, S ^e   Hasson, C W ^e   O'Malley, T ^e   Weil, M A ^e   Aguirre, G A ^c   Brown, D E ^d   Haskins, M E ^e  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Animal model; Cat; Glycosaminoglycan; Immune response; Lysosomal storage disorder; Mucopolysaccharidosis; L iduronidase

Indexed keywords

GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN G ANTIBODY; LEVO IDURONIDASE; LYSOSOME ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BLOOD BRAIN BARRIER; CAT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; ENZYME REPLACEMENT; EXTRACELLULAR SPACE; GAUCHER DISEASE; GENE THERAPY; HURLER SYNDROME; IMMUNE RESPONSE; KIDNEY CORTEX; LYSOSOME STORAGE DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

ANIMALIA; FELIDAE; FELIS CATUS;

EID: 0035718871     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2000.3140     Document Type: Article

References (31)

1. The mucopolysaccharidoses
2. Beta glucuronidase deficiency in a dog: A model of mucopolysaccharidosis VII
3. Murine mucopolysaccharidosis type I: Targeted disruption of the murine alpha-L-iduronidase gene
4. Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats
5. The defect in Hurler Hunter syndromes, II. Deficiency of specific factors involved in mucopolysaccharide degradation
6. The mucopolysaccharidoses
7. Human β-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells
8. Evidence for specific recognition sites mediating clearance of lysosomal enzymes in vivo
9. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation
10. Recognition and receptor-mediated uptake of a lysosomal enzyme, α-L-iduronidase, by cultured human fibroblasts
11. Enzyme replacement therapy for Gaucher disease: Critical investigations beyond demonstration of clinical efficacy
12. Enzyme replacement therapy for murine mucopolysaccharidosis type VII
13. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome
14. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I
15. Enzyme replacement therapy in feline mucopolysaccharidosis I
16. Overexpression of the human lysosomal enzyme α-L-iduronidase in Chinese hamster ovary cells
17. Simultaneous preparation and quantification of proteoglycans by precipitation with Alcian blue
18. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts
19. The pattern of mammalian brain gangliosideso-II
20. Ganglioside structure: Isolation and analysis
21. Quantitative estimation of sialic acids: A colorimetric resorcinol-hydrochloric acid method
22. Growth of ectopic dendrites on cortical pyramidal neurons correlates with abnormal accumulation of GM2 ganglioside
23. Enzyme replacement in canine model of Hurler syndrome
24. Enzyme replacement with recombinant β-glucuronidase in the newborn mucopolysaccharidosis type VII mouse
25. A less costly regimen of Alglucerase to treat Gaucher's disease
26. Postmortem findings in the Hurler-Scheie syndrome (mucopolysaccharidosis I-H/S)
27. Enzyme replacement therapy in mucopolysaccharidosis I: Altered distribution and targeting of alpha-L-iduronidase in immunized rats
28. Enzyme replacement therapy in mucopolysaccharidosis. VI. Evidence for immune responses and altered efficacy of treatment in animal models
29. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase
30. Humoral immune response limits gene therapy in canine MPS I